Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€188.40

€188.40

-0.740%
-1.4
-0.740%
€275.00
 
22:26 / Tradegate WKN: 716560 / Symbol: SARTF / Name: Sartorius / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Sartorius AG ST Stock

The price for the Sartorius AG ST stock decreased slightly today. Compared to yesterday there is a change of -€1.400 (-0.740%).
Currently there is a rather positive sentiment for Sartorius AG ST with 5 Buy predictions and 0 Sell predictions.
With a target price of 275 € there is a positive potential of 45.97% for Sartorius AG ST compared to the current price of 188.4 €.
Our community identified positive and negative aspects for Sartorius AG ST stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Sartorius AG ST stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.

Sartorius is a German-based biotech and laboratory equipment company that is listed on the Frankfurt Stock Exchange under the symbol SARTF. The company provides products and services for the pharmaceutical, biotech, and food industries, including laboratory instruments, consumables, and services. Sartorius has a global presence with operations in Europe, Asia, and the Americas, and has a strong reputation for innovation, quality, and reliability. The company's stock has performed well in recent years, reflecting its solid financial results and growth prospects in the life sciences industry.

Pros and Cons of Sartorius AG ST in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sartorius AG ST vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sartorius AG ST -0.740% 6.419% -1.869% -27.447% -28.409% -54.893% 12.836%
Sartorius AG VZO 2.930% 4.548% -4.695% -30.074% -32.098% -49.889% 23.520%
Healthequity Inc. - -0.645% -1.282% 35.088% 29.412% 11.240% -
Integer Hldg - 0.000% -2.752% 31.677% 19.101% 33.333% 47.838%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-20

Sartorius is an established player in the Healthcare Equipment & Supplies industry, and their financials reflect a strong position in the market. The company has displayed consistent growth in revenues, assets, and shareholder equity over the years. However, there are certain aspects of their financials that may warrant closer scrutiny.

Increasing Revenue: Sartorius has experienced consistent growth in its total revenue over the past three years, increasing from €2,335,657,000 in 2020 to €4,174,700,000 in 2022.

Growth in Total Assets: The company has reported a substantial increase in its total assets, which rose from €4,697,348,000 in 2020 to €6,977,700,000 in 2022. This demonstrates a strong financial position and the potential for further growth.

Comments

systinvest bought the security Sartorius AG in his wikifolio Aktienwertselektion mit System.
Show more

News

EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret
EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO,  Joachim Kreuzburg will not pursue another term in office : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA